SCHEMBL6030352

SCHEMBL6030352

CCCCCCCCNC(=O)Nc1sc(C(=O)OC(C)CCCCCC)c(C)c1C(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.39
TSHR P16473 2/20 0.39
HPGD P15428 6/20 0.39
FAAH O00519 4/20 0.38
HSD17B10 Q99714 1/20 0.37
NPSR1 Q6W5P4 2/20 0.36
MAPT P10636 1/20 0.36
APOBEC3G Q9HC16 1/20 0.36
EPHX1 P07099 2/20 0.36
PKM P14618 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
EPHX2 P34913 2/20 0.35
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6030207 0.90 ALDH1A1 (0.40) ALDH1A1TSHRHPGDHSD17B10NPSR1
SCHEMBL6029738 0.88 ALDH1A1 (0.42) ALDH1A1TSHRHPGDFAAHHSD17B10
SCHEMBL6030673 0.87 PKM (0.42) ALDH1A1TSHRHPGDHSD17B10NPSR1
SCHEMBL6029710 0.85 ALDH1A1 (0.43) ALDH1A1TSHRHPGDHSD17B10NPSR1
SCHEMBL6031046 0.85 ALDH1A1 (0.42) ALDH1A1TSHRHPGDHSD17B10NPSR1
SCHEMBL6029757 0.85 ALDH1A1 (0.43) ALDH1A1TSHRHPGDHSD17B10NPSR1
SCHEMBL6029669 0.85 ALDH1A1 (0.43) ALDH1A1TSHRHPGDHSD17B10NPSR1
SCHEMBL6030054 0.85 ALDH1A1 (0.43) ALDH1A1TSHRHPGDHSD17B10NPSR1
SCHEMBL6030770 0.85 ALDH1A1 (0.42) ALDH1A1TSHRHPGDHSD17B10NPSR1
SCHEMBL6029900 0.85 ALDH1A1 (0.42) ALDH1A1TSHRHPGDHSD17B10NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7064122-B2 Pancreatic lipase inhibitor compounds, their synthesis and use OSI PHARMACEUTICALS, INC. (US) 2006-06-20 US disclosed
EP-1467978-A4 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARM INC (US) 2005-11-02 EP disclosed
EP-1467978-A1 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI Pharmaceuticals, Inc. (US) 2004-10-20 EP disclosed
US-20030195199-A1 Pancreatic lipase inhibitor compounds, their synthesis and use OSI PHARMACEUTICALS, INC. 2003-10-16 US disclosed
WO-2003053944-A1 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARMACEUTICALS, INC. (US) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195199-A1 Pancreatic lipase inhibitor compounds, their synthesis and use PNLIP, LIPC, CEL ALDH1A1 1832/4885TSHR 212/4885HPGD 4273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.